Biocryst Pharmaceuticals Inc. BCRX

NAS: BCRX | ISIN: US09058V1035 7/06/2023

8,810 USD (+3,28%)

(+3,28%) 7/06/2023

Toon enkel gratis nieuws

19 maart 2021 · BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development Officer · Persbericht

11 maart 2021 · Early Access to BioCryst’s Berotralstat Granted for HAE Patients in France · Persbericht

25 februari 2021 · BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema · Persbericht

9 februari 2021 · BioCryst to Present Data at 2021 American Academy of Allergy, Asthma & Immunology Annual Meeting · Persbericht

3 februari 2021 · BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older · Persbericht

22 januari 2021 · BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema · Persbericht

7 januari 2021 · BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

6 januari 2021 · BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe